Avan Armaghani, MD

Cancer Focus:
Breast Cancer

Education & Training

Fellowship:

• Shands Hospital at the University of Florida - Hematology & Oncology

Residency:

• Shands Hospital at the University of Florida -

Medical School:

• University of Florida College of Medicine - MD

• Soliman H, Aldrich A, Abdo N, Han H, Soyano A, Costa R, Armaghani A, Kiluk J, Khakpour N, Lee MC, Hoover S, Laronga C, Niell B, Mooney B, Weinfurtner RJ, Rosa M, Czerniecki B. A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER- breast cancer. NPJ Breast Cancer. 2025 Mar.11(1):29. Pubmedid: 40097486. Pmcid: PMC11914126.
• Ahmed KA, Kim Y, Armaghani AJ, Arrington JA, Costa RL, Czerniecki BJ, Diaz R, Dowell RA, Extermann M, Forsyth PA, Lee KT, Loftus L, Mills MN, Phuoc VH, Rosa M, Soliman HH, Sam CS, Washington IR, Soyano AE, Han HS. Phase II trial of brain MRI surveillance in stage IV breast cancer. Neurooncol. 2025 Jul.27(6):1550-1558. Pubmedid: 39851040. Pmcid: PMC12309701.
• Han HS, Aldrich AL, Garg SK, Weinfurtner RJ, Nguyen JV, Mo Q, Whiting J, Childress J, Soliman H, Costa R, Armaghani A, Soyano A, Kiluk J, Hoover S, Lee MC, Khakpour N, Shenoi N, Jameel Z, Koski GK, Czerniecki BJ. Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in ERBB2 Breast Cancer: A Nonrandomized Clinical Trial. JAMA Oncol. 2025 Feb.11(2):119-127. Pubmedid: 39636623. Pmcid: PMC11622104.
• Basta A, Lien K, Sun W, Whiting J, Armitage M, Soyano AE, Armaghani A, Loftus L, O Apos Connor T, Dvir K, Han HS, Soliman H, Czerniecki BJ, Costa RLB. A Real-World Single-Center Cohort Study on the Tolerability of Trastuzumab Deruxtecan for HER2+ Metastatic Breast Cancer. Oncology-Basel. 2025 Aug.1-10. Pubmedid: 40759100.
• Ahmed KA, Kim Y, Kim S, Wang MH, DeJesus M, Arrington JA, Soyano AE, Armaghani AJ, Costa RLB, Loftus LS, Rosa M, Caudell JJ, Diaz R, Etame AB, Tran ND, Soliman H, Czerniecki BJ, Forsyth PA, Yu HM, Han HS. Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: long-term results and biomarker analysis from a non-randomized, open-label, phase Ib study. J Immunother Cancer. 2025 Apr.13(4). Pubmedid: 40295143. Pmcid: PMC12039042.
• Soliman H, Hogue D, Han H, Mooney B, Costa R, Lee MC, Niell B, Williams A, Chau A, Falcon S, Soyano A, Armaghani A, Khakpour N, Weinfurtner RJ, Hoover S, Kiluk J, Laronga C, Rosa M, Khong H, Czerniecki B. Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial. Nat Med. 2023 Feb.29(2):450-457. Pubmedid: 36759673.
• Soliman H, Hogue D, Han H, Mooney B, Costa R, Lee MC, Niell B, Williams A, Chau A, Falcon S, Soyano A, Armaghani A, Khakpour N, Weinfurtner RJ, Hoover S, Kiluk J, Laronga C, Rosa M, Khong H, Czerniecki B. Author Correction: Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial. Nat Med. 2023 Dec.29(12):3270. Pubmedid: 36932246.
• Kalra M, Henry E, McCann K, Karuturi MS, Bustamante Alvarez JG, Parkes A, Wesolowski R, Wei M, Mougalian SS, Durm G, Qin A, Schonewolf C, Trivedi M, Armaghani AJ, Wilson FH, Iams WT, Turk AA, Vikas P, Cecchini M, Lubner S, Pathak P, Spencer K, Koshkin VS, Labriola MK, Marshall CH, Beckermann KE, Sharifi MN, Bejjani AC, Hotchandani V, Housri S, Housri N. Making National Cancer Institute-Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study. JMIR Cancer. 2022 May.8(2):e33859. Pubmedid: 35588361. Pmcid: PMC9164098.
• Ahmed KA, Kim Y, Arrington JA, Kim S, DeJesus M, Soyano AE, Armaghani AJ, Costa RLB, Khong HT, Loftus LS, Rosa M, Caudell JJ, Diaz R, Robinson TJ, Etame AB, Tran ND, Sahebjam S, Soliman HH, Czerniecki BJ, Forsyth PA, Yu HM, Han HS. Nivolumab and Stereotactic Radiosurgery for Patients With Breast Cancer Brain Metastases: A Nonrandomized, Open-Label Phase 1b Study. Adv Radiat Oncol. 2021 Sep.6(6):100798. Pubmedid: 34934864. Pmcid: PMC8655428.
• Barakat E, Bibok A, Rishi A, Ahmed A, Frakes JM, Hoffe SE, Armaghani AJ, Soyano AE, Costa RLB, El-Haddad G, Choi J, Kis B. Transarterial Yttrium-90 Glass Microsphere Radioembolization of Chemotherapy-Refractory Breast Cancer Liver Metastases: Results of a Single Institution Retrospective Study. Adv Radiat Oncol. 2021 Oct.7(1):100838. Pubmedid: 35071835. Pmcid: PMC8767250.
• Sun J, Zhong X, Ma J, Sun W, Han HS, Soliman HH, Loftus LS, Costa RLB, Armaghani AJ, Soyano-Muller AE, Czerniecki BJ, Lee MC, Kiluk JV, Khakpour N, Hoover SJ, Laronga C, Khong HT. Real-world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia. Cancer Med. 2021 Nov.10(21):7665-7672. Pubmedid: 34590788. Pmcid: PMC8559460.
• Moy B, Rumble RB, Come SE, Davidson NE, Di Leo A, Gralow JR, Hortobagyi GN, Yee D, Smith IE, Chavez-MacGregor M, Nanda R, McArthur HL, Spring L, Reeder-Hayes KE, Ruddy KJ, Unger PS, Vinayak S, Irvin WJ, Armaghani A, Danso MA, Dickson N, Turner SS, Perkins CL, Carey LA. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. J Clin Oncol. 2021 Dec.39(35):3938-3958. Pubmedid: 34324366.
• Armaghani AJ, Han HS. Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data. Breast Cancer (Dove Med Press). 2020 Nov.12:251-258. Pubmedid: 33239910. Pmcid: PMC7680678.
• Figura NB, Rizk VT, Armaghani AJ, Arrington JA, Etame AB, Han HS, Czerniecki BJ, Forsyth PA, Ahmed KA. Breast leptomeningeal disease: a review of current practices and updates on management. Breast Cancer Res Treat. 2019 Sep.177(2):277-294. Pubmedid: 31209686.
• Armaghani A, Hernandez Gonzalo D, Daily K. Hepatoid adenocarcinoma of the colon. BMJ Case Rep. 2015 Apr.2015. Pubmedid: 25883249. Pmcid: PMC4401922.
• Crucian GP, Armaghani S, Armaghani A, Foster PS, Burks DW, Skoblar B, Drago V, Heilman KM. Dopamine does not appear to affect mental rotation in Parkinson's disease. J Mov Disord. 2014 Oct.7(2):77-83. Pubmedid: 25360231. Pmcid: PMC4213535.
• Iqbal S, Armaghani A, Aiyer R, Kazory A. Methotrexate nephrotoxicity: Novel treatment, new approach. J Oncol Pharm Pract. 2013 Dec.19(4):373-376. Pubmedid: 24255083.
• Crucian GP, Armaghani S, Armaghani A, Foster PS, Burks DW, Skoblar B, Drago V, Heilman KM. Visual-spatial disembedding in Parkinson's disease. J Clin Exp Neuropsychol. 2010 Feb.32(2):190-200. Pubmedid: 19484649.